期刊
VACCINE
卷 25, 期 17, 页码 3277-3283出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2007.01.005
关键词
modified vaccinia virus Ankara; HIV-1; clinical study
资金
- MRC [G0502048, MC_U137884177, MC_U137884179] Funding Source: UKRI
- Medical Research Council [G0502048, MC_U137884179, MC_U137884177] Funding Source: researchfish
- Medical Research Council [MC_U137884177, MC_U137884179, G0502048] Funding Source: Medline
The safety of attenuated poxviruses in HIV-1-infected individuals is an important consideration in their application as vaccine vectors, first, because new HIV-1 infections may occur in vaccine trials involving persons at high risk of infection and secondly, therapeutic vaccinations are a potential means to enhance virus-specific immune responses once infection has occurred. We administered a candidate modified vaccinia virus Ankara-vectored HIV-1 vaccine, MVA.HIVA, by intradermal injection to 16 chronically infected adults during highly active antiretroviral therapy. Vaccinations were well tolerated and there were no serious adverse events. No breakthrough viraemia occurred after immunisations or throughout follow-up. These data confirm the safety of MVA.HIVA in HIV-1-infected individuals and provide Support for further evaluation of MVA-vectored vaccines in prophylactic and therapeutic immunisation strategies. (c) 2007 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据